Article

Molecule engineered to target neovascularization in AMD

A genetically engineered molecule designed to kill cancers by destroying their rapidly growing blood vessels offers a new line of attack against age-related macular degeneration (AMD) and other retinal conditions, said Alan Garen, PhD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
(Image credit: AdobeStock/auremar)
April 7th 2025

Orasis Pharmaceuticals’ prescription pilocarpine hydrochloride ophthalmic solution 0.4% (Qlosi) for presbyopia available in the US

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: Australian Society of Ophthalmologists)
March 8th 2025

Australian Society of Ophthalmologists welcomes Katrina Ronne as the first woman in its CEO role

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

AI and eye tracking: Technological companions to assess amblyopia in pediatric patients
March 3rd 2025

AI and eye tracking: Technological companions to assess amblyopia in pediatric patients

(Image credit: StockAdobe/Andrija)
February 25th 2025

Australian Society of Ophthalmologists announces new board appointments

© 2025 MJH Life Sciences

All rights reserved.